增殖性糖尿病视网膜病变诊断后第一年治疗趋势
该研究基于TriNetX美国协作网络2005至2024年数据,纳入14,768例新诊断增殖性糖尿病视网膜病变患者,分析诊断后一年内初始治疗方式的变化。结果显示,全视网膜光凝单药治疗比例从2005年的100%降至2024年的21.5%,而联合治疗和抗VEGF单药治疗分别占42.4%和36.1%,整体趋势显著。
要点
- 2024年联合治疗成为最常用初始方案(42.4%),抗VEGF单药治疗占36.1%,全视网膜光凝单药治疗占21.5%。
- 2015年后全视网膜光凝单药治疗年相对下降速率加快(5.22%/年 vs 3.56%/年,P=0.0338)。
- 2015年后抗VEGF单药治疗年相对上升速率加快(2.03%/年 vs 1.58%/年,P=0.0283)。
核心结论
- 过去二十年间,增殖性糖尿病视网膜病变的管理从全视网膜光凝单药治疗转向抗VEGF治疗,包括联合治疗和单药治疗。
研究设计与样本
- 横断面时间序列研究,使用TriNetX美国协作网络2005至2024年数据,纳入14,768例新诊断增殖性糖尿病视网膜病变患者。
主要发现
- 2005年全视网膜光凝单药治疗占初始治疗的100%。
- 2024年联合治疗占42.4%,抗VEGF单药治疗占36.1%,全视网膜光凝单药治疗占21.5%,整体趋势均P<0.0001。
- 2015年后全视网膜光凝单药治疗年相对下降速率显著大于2015年前(5.22% vs 3.56%/年,P=0.0338)。
- 2015年后抗VEGF单药治疗年相对上升速率显著大于2015年前(2.03% vs 1.58%/年,P=0.0283)。
关键数值与推荐
- 初始治疗方式定义为诊断后一年内接受的以下之一:全视网膜光凝单药治疗、抗VEGF单药治疗或联合治疗(全视网膜光凝+抗VEGF)。
- 趋势比较采用Cochran-Armitage检验。
临床怎么用
- 临床实践中,增殖性糖尿病视网膜病变的初始治疗选择已更多倾向于抗VEGF治疗,包括联合治疗和单药治疗,全视网膜光凝单药治疗使用减少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To examine trends in initial treatment modality for patients diagnosed with proliferative diabetic retinopathy (PDR). METHODS: A cross-sectional time series was performed between 2005 and 2024 using the TriNetX US Collaborative Network. Patients with new-onset PDR were identified, and initial treatment modality within one year after diagnosis was recorded. The proportion of patients managed with panretinal photocoagulation (PRP) monotherapy, antivascular endothelial growth factor (anti-VEGF) monotherapy, or combination therapy (PRP + anti-VEGF) were compared using Cochran-Armitage tests for trend. Rates of change in treatment proportionality were compared between 2005 to 2014 and 2015 to 2024, the time period before and after the publication of the Diabetic Retinopathy Clinical Research Network Protocol S. RESULTS: A total of 14,768 patients with newly diagnosed PDR met inclusion criteria. In 2005, PRP monotherapy accounted for 100% of initial treatment. In 2024, combination therapy was the most commonly used treatment modality, accounting for 42.4% of cases (overall trend, P < 0.0001), followed by anti-VEGF monotherapy at 36.1% (overall trend, P < 0.0001), and PRP monotherapy at 21.5% (overall trend, P < 0.0001). After 2015, the annual rate of change differed significantly compared with the pre-2015 period for both monotherapies. The proportion of patients treated with PRP monotherapy showed a steeper relative annual decline (5.22% vs. 3.56% per year, P = 0.0338), while anti-VEGF monotherapy demonstrated a greater relative annual increase (2.03% vs. 1.58% per year, P = 0.0283). CONCLUSION: Management of PDR has shifted over the past two decades from PRP monotherapy toward anti-VEGF therapy, including both combination therapy and monotherapy.
引用
- Zhang C, Bhatnagar A, Ersan S, et al. TRENDS IN THE MANAGEMENT OF PROLIFERATIVE DIABETIC RETINOPATHY IN THE FIRST YEAR AFTER DIAGNOSIS. Retina. 2026. PMID: 41983931. doi:10.1097/IAE.0000000000004861
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。